HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
- David Straus
- , John Radford
- , Joseph Connors
- , Won Seog Kim
- , Andrea Gallamini
- , Radhakrishnan Ramchandren
- , Jonathan Friedberg
- , Ranjana Advani
- , Martin Hutchings
- , Andrew Evens
- , Piotr Smolewski
- , Kerry Savage
- , Nancy Bartlett
- , Hyeon Seok Eom
- , Jeremy Abramson
- , Cassie Dong
- , Frank Campana
- , Keenan Fenton
- , Markus Puhlmann
- , Stephen Ansell
- Memorial Sloan Kettering Cancer Center
- British Columbia Cancer Agency Branch
- Centre René Huguenin
- The University of Tennessee Graduate School of Medicine
- University of Rochester
- Stanford University
- Copenhagen University Hospital
- The State University of New Jersey
- Medical University of Lodz
- Washington University School of Medicine
- National Cancer Center, Gyeonggi
- Massachusetts General Hospital
- Takeda Development Center Americas Inc
- Seagen Inc.
- Mayo Clinic (HQ)
Research output: Chapter in Book/Conference proceeding › Conference contribution › peer-review